To test whether RASA2 ablation in TCR T cells could improve control of a liquid tumour bearing the same NY-ESO-1 antigen, we injected Nalm6 leukaemia cells engineered to express NY-ESO-1 on cognate major histocompatibility complex class I molecules (MHCI) into the tail vein of mice (Fig. 4c). The gene discussed is RASA2; the disease is neoplasm.